81 related articles for article (PubMed ID: 5327216)
21. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N
Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340
[TBL] [Abstract][Full Text] [Related]
22. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
23. [Hematopoiesis disorders in acute alcoholism].
Paraf A; Coste T; Gouffier E
Ann Med Interne (Paris); 1971; 122(6):689-700. PubMed ID: 5113440
[No Abstract] [Full Text] [Related]
24. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
26. [Treatment with 5-fluorouracil: randomized study comparing an oral preparation with intravenous administration].
Veronesi A; Talamini R; Mauro Trovò G; Tirelli U; Galligioni E; Tumolo S; Grigoletto E
Clin Ter; 1981 May; 97(4):389-93. PubMed ID: 7018819
[No Abstract] [Full Text] [Related]
27. [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Konishi K; Yabushita K; Taguchi T; Ota J; Takashima S; Abe T; Kikkawa N; Yasutomi M; Sowa M; Maehara Y
Gan To Kagaku Ryoho; 1995 Jun; 22(7):925-32. PubMed ID: 7793998
[TBL] [Abstract][Full Text] [Related]
28. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
29. [Combined cytostatic treatment of solid tumours with cyclophosphamide (Endoxan), vincristine, methylaminopterin (Methotrexate) and 5-fluorouracil].
Brincker H
Ugeskr Laeger; 1971 May; 133(19):926-9. PubMed ID: 5559763
[No Abstract] [Full Text] [Related]
30. [Phase III clinical study of a new anticancer drug atofluding].
Li Q; Feng FY; Han J; Sui GJ; Zhu YG; Zhang Y; Zhang ZH; Li L; Wang PH; Zhou MZ; Zhang YC
Ai Zheng; 2002 Dec; 21(12):1350-3. PubMed ID: 12520746
[TBL] [Abstract][Full Text] [Related]
31. [Clinical use of 5-fluorouracil in surgical field].
Suzuki T; Nishimura G; Imamura K; Sugahara K; Fujii Y
Gan No Rinsho; 1969 May; 15(5):459-68. PubMed ID: 5387578
[No Abstract] [Full Text] [Related]
32. TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
HURLEY JD
Acta Unio Int Contra Cancrum; 1964; 20():363-5. PubMed ID: 14151930
[No Abstract] [Full Text] [Related]
33. [Acute cardiotoxicity from 5-fluorouracil: un underestimated toxicity].
Bertolini A; Fiumanò M; Muffatti A; Pedroncelli S; Doria A; Codazzi G; Giustiniani S; Scarinci A; Redaelli G
Minerva Cardioangiol; 1999; 47(7-8):269-73. PubMed ID: 10582438
[TBL] [Abstract][Full Text] [Related]
34. Myelotoxicity from chemotherapy.
Daniel D; Crawford J
Semin Oncol; 2006 Feb; 33(1):74-85. PubMed ID: 16473646
[TBL] [Abstract][Full Text] [Related]
35. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
[TBL] [Abstract][Full Text] [Related]
36. A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Ahmann DL; Moertel CG; Bisel HF; Hahn RG; Schutt AJ; Dines DE
Oncology; 1974; 29(2):166-71. PubMed ID: 4836677
[No Abstract] [Full Text] [Related]
37. [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Takeda S; Taguchi T; Ohta J; Kurihara M; Abe T; Ohtani T; Yonemura Y; Ohno T; Hirabayashi N; Nakano S
Gan To Kagaku Ryoho; 1995 Jun; 22(7):903-10. PubMed ID: 7793996
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
Long HJ; Nelimark RA; Su JQ; Garneau SC; Levitt R; Goldberg RM; Poon MA; Kugler JW
Gynecol Oncol; 1994 Aug; 54(2):180-3. PubMed ID: 8063243
[TBL] [Abstract][Full Text] [Related]
39. [Nursing care in adverse effects of chemotherapy].
Simonetti G
Tijdschr Ziekenverpl; 1981 Jul; 34(15):644-50. PubMed ID: 6913266
[No Abstract] [Full Text] [Related]
40. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
